Please login to the form below
neurodegenerative diseases
This page shows the latest neurodegenerative diseases news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk to buy Dicerna Pharmaceuticals for $3.3bn
Dicerna believes its proprietary GalXC and GalXC-Plus RNAi technologies will lead to the development of RNAi-based therapies to treat both rare and more prevalent diseases. ... Collectively, they have more than 20 active discovery, preclinical or
Latest news
-
Muna raises $73m to advance neurodegenerative disease-focused small molecule pipeline
Muna Therapeutics has launched with $73m series A funding to advance its small molecule therapeutics pipeline focused on neurodegenerative diseases. ... Backed by Novo Holdings, Muna is focused on the development of novel small molecule therapeutics
-
GlaxoSmithKline agrees $2.2bn dementia mAb deal with Alector
The focus of the deal is two clinical-stage monoclonal antibodies in development for a number of neurodegenerative diseases. ... neurodegenerative diseases,” said Hal Barron (pictured right), chief scientific officer and president R&D, GSK.
-
Merck & Co signs deal with Amathus for neurodegenerative diseases
Merck &Co has signed a strategic collaboration agreement with Amathus Therapeutics focused on developing novel small molecule candidates for neurodegenerative diseases. ... The Merck neuroscience team is an ideal partner to translate this novel approach
-
AbbVie buys exclusive right to acquire Mitokinin’s Parkinson’s asset
The company is developing PINK1 targeted therapies for the treatment of neurodegenerative and mitochondrial diseases. ... If AbbVie does exercise its option to license Mitokinin’s PINK1 asset, it will add a new candidate to its neurodegenerative
-
Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors
Companies will co-develop molecules for the treatment of immunological and neurodegenerative diseases. ... The ethos behind RIPK1 inhibitor development is to offer a new kind of approach towards treating a range of autoimmune, inflammatory and
More from news
Approximately 3 fully matching, plus 65 partially matching documents found.
Latest Intelligence
-
Piloting a route to the biosimilars opportunities in Europe
Biological medicines represent a major advance in the treatment of serious pathological conditions such as cancer, neurodegenerative and autoimmune diseases, in the form of biosimilars. ... For orphan designations (medicine for rare diseases),
-
Alzheimer’s disease: the search for a cure
Advances in technology are providing huge opportunities to intervene decades earlier, when these diseases first start to take hold. ... That’s where the Early Detection of Neurodegenerative diseases (EDoN) initiative comes in.
-
The search for treatments for Parkinson’s disease
and a decade as senior director of neurodegenerative diseases research at Merck Serono where he served as its leader for in vitro pharmacology in neurology, including in multiple sclerosis, Parkinson’s ... and Alzheimer’s diseases.
-
Alzheimer’s: the search for a cure
big diseases in the field, such as Alzheimer’s, is too limited to make near-term success likely. ... Based on what we felt was the state of the art in terms of understanding the pathogenesis of major diseases, especially neurodegenerative diseases, and
-
A roadmap to the successful treatment of Alzheimer’s disease
Nevertheless, strategies for developing successful therapeutic interventions are shifting. We have developed a five-point roadmap to successful treatments for Alzheimer’s disease and neurodegenerative diseases. ... Hyper-stimulation of microglial cells
More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.
Latest appointments
-
Biogen appoints executive VP, corporate development
to tackle unmet needs in neurological diseases.”. ... to expand the company's portfolio of therapies for people living with serious neurodegenerative diseases.”.
-
Prevail Therapeutics adds to its board of directors
Francois Nader joins the biotech. Prevail Therapeutics, a biotechnology company focused on the development of gene therapies for patients with neurodegenerative diseases, has strengthened its board of directors with the addition ... The Prevail team has
-
Asceneuron appoints chief medical officer
Novartis’ Michael Ryan joins the neurodegenerative diseases specialist. Lausanne, Switzerland-based Asceneuron has appointed Michael Ryan as its new chief medical officer. ... He joins the neurodegenerative diseases specialist from Novartis, where he
-
UK Dementia Research Institute names director
Prof De Strooper is currently a professor of molecular medicine at the University of Leuven and leads its laboratory for the research of neurodegenerative diseases.
-
Merck’s Michel Vounatsos moves to Biogen
neurodegenerative and rare diseases around the world.
More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest from PMHub
-
Impetus Digital Fireside Chat With Richie Bavasso From NqMedical
Richie Bavasso, founder and CEO of nQMedical, discusses everything from digital therapeutics, diagnostics, and other data-driven solutions for neurodegenerative diseases to Richie’s favorite media outlets, his work at nQMedical,
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Gilead to pay $745m for three oncology programmes from Arcus Biosciences
- Novo Nordisk to buy Dicerna Pharmaceuticals for $3.3bn
- AstraZeneca/Moderna’s mRNA treatment for heart failure looks promising
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- From Academics to Entrepreneurship: How Tech is Revolutionizing the Diagnostics Landscape
- Impetus Digital wins Canada’s Most Admired Corporate Cultures Awards 2021
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Regeneron signs $900m cancer and infectious disease deal with Nykode
- Webinar:
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Live Webinar: From Academics to Entrepreneurship: How Tech is Revolutionizing the Diagnostics Landscape
- Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
- Live Webinar: Gamifying Surgical Training to Improve Patient Outcomes
- AZ, Amgen’s tezepelumab reduces asthma exacerbations in broad patient population
- NICE recommends long-acting HIV therapy developed by ViiV Healthcare and Janssen
PMHub
Onyx Health Ltd
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
